Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.40 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8183400 | 0.79 | POLB (0.50) | CA1CA2POLBALDH1A1HSD17B10 | |
| SCHEMBL18245343 | 0.79 | POLB (0.50) | CA1CA2POLBALDH1A1HSD17B10 | |
| SCHEMBL13948301 | 0.78 | CA1 (0.53) | CA1CA2ALDH1A1HSD17B10CYP2A6 | |
| SCHEMBL646163 | 0.77 | CA1 (0.52) | CA1CA2ALDH1A1HSD17B10CYP2A6 | |
| SCHEMBL15745354 | 0.76 | CHAT (0.47) | CA1CA2POLBALDH1A1HSD17B10 | |
| SCHEMBL16581281 | 0.75 | CA1 (0.50) | CA1CA2ALDH1A1HSD17B10CYP2A6 | |
| SCHEMBL1644856 | 0.75 | CA1 (0.55) | CA1CA2ALDH1A1HSD17B10CYP2A6 | |
| SCHEMBL1644197 | 0.75 | CA1 (0.50) | CA1CA2ALDH1A1HSD17B10CYP2A6 | |
| SCHEMBL11556490 | 0.75 | CYP2A6 (0.54) | CA1CA2ALDH1A1HSD17B10CYP2A6 | |
| SCHEMBL5950664 | 0.75 | TSHR (0.54) | CA1CA2ALDH1A1HSD17B10CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11446298-B2 | Pyrimidine derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-09-20 | — | — | US | disclosed |
| EP-3625223-B1 | PYRIMIDINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-08-11 | — | — | EP | disclosed |
| US-20200108068-A1 | PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2020-04-09 | — | — | US | disclosed |
| EP-3625223-A1 | PYRIMIDINE DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2020-03-25 | — | — | EP | disclosed |
| CN-110621667-A | Pyrimidine derivatives | 爱杜西亚药品有限公司 | 2019-12-27 | — | — | CN | disclosed |
| WO-2018210992-A1 | PYRIMIDINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-11-22 | — | — | WO | disclosed |
| CN-105392778-B | polycyclic compound and organic light emitting device using the same | 喜星素材株式会社 | 2018-05-25 | — | — | CN | disclosed |
| CN-104892502-B | It is used as the aryl-pyridine of aldosterone synthase inhibitors | 诺华股份有限公司 | 2017-08-04 | — | — | CN | disclosed |
| CN-106478500-A | Carboxylic acid-substituted（Miscellaneous）Aromatic ring analog derivative and its production and use | 广东东阳光药业有限公司 | 2017-03-08 | — | — | CN | disclosed |
| CN-103180312-B | Be used for the treatment of or prevent the heterogeneous ring compound of the disorder that the reduction because of the nerve conduction of thrombotonin, norepinephrine or Dopamine HCL causes | OTSUKA PHARMACEUTICAL CO.,LTD. (JP) | 2016-01-20 | — | — | CN | disclosed |
| CN-104892502-A | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG | 2015-09-09 | — | — | CN | disclosed |
| CN-102803217-B | Aryl pyridines as aldosterone synthase inhibitors | NOVARTIS AG | 2015-06-17 | — | — | CN | disclosed |
| CN-102317296-B | Fused aromatic PTP-1B inhibitors | KANEQ PHARMA INC | 2015-05-27 | — | — | CN | disclosed |
| CN-103180312-A | Heterocyclic compounds for treating or preventing disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine | OTSUKA PHARMA CO LTD | 2013-06-26 | — | — | CN | disclosed |
| US-20050182269-A1 | Process for the preparation of 3-cyano-1-naphthoic acid and some analogues thereof | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | US | disclosed |
| EP-1517884-A1 | A PROCESS FOR THE PREPARATION OF 3-CYANO-1-NAPHTHOIC ACID AND SOME ANALOGUES THEREOF | AstraZeneca AB (SE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004000792-A1 | A PROCESS FOR THE PREPARATION OF 3-CYANO-1-NAPHTHOIC ACID AND SOME ANALOGUES THEREOF | ASTRAZENECA AB (SE) | 2003-12-31 | — | — | WO | disclosed |
| CN-1265645-A | Urokinase inhibitors | ABBOTT LAB (US) | 2000-09-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182269-A1 | Process for the preparation of 3-cyano-1-naphthoic acid and some analogues thereof | CYP8B1, CYP51A1, NISCH | CA1 777/4885CA2 606/4885POLB 350/4885 |
| US-11446298-B2 | Pyrimidine derivatives | PTGER1, PTGER4, PTGER2 | CA1 4739/4885CA2 4017/4885POLB 1046/4885 |
| US-20200108068-A1 | PYRIMIDINE DERIVATIVES | PTGER1, PTGER4, PTGER2 | CA1 4739/4885CA2 4017/4885POLB 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.